Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2024-11-22 00:00:00 ET · period of report 2024-11-22 · accession 0001140361-24-047702 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-11-22	2024-11-22	ADMA	Tade Brad L.	CFO, Treas	S - Sale	$21.15	-15.0K	199.4K	-7%	-$317.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-11-22	S	D	15,000	$21.15	199,433	D	—	—	(F1) These shares represent restricted stock units ("RSUs") that were granted on June 26, 2023 and vested on June 26, 2024. (F4) (continued from footnote 3) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs. (F2) Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; (F3) (continued from footnote 2) (ii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;